European equities traded in the US as American depositary receipts started the week modestly lower late Monday morning, declining 0.26% to 1,486.79 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and biopharmaceutical company Cellectis (CLLS), which rose 1.5% and 1.3%, respectively. They were followed by software firm SAP (SAP) and telecommunications company Ericsson (ERIC), which were up 0.9% and 0.8%, respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm Evaxion (EVAX), which fell 5.5% and 4.4%, respectively. They were followed by accommodations booking company trivago (TRVG) and semiconductor company Sequans Communications (SQNS), which lost 3.8% and 3.4%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which advanced 5.1% and 2.4%, respectively. They were followed by telecommunications operator Vodafone Group (VOD) and financial services company HSBC (HSBC), which increased 1.8% and 0.9%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Bicycle Therapeutics (BCYC) and NuCana (NCNA), which dropped 4.3% and 2.6%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and oil and gas company Shell (SHEL), which were down 2.5% and 2.1%, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.